In the management of non-Hodgkin lymphoma (NHL), multiple mechanisms of therapy have been developed.
These therapies include anti-CD20 antibodies and chimeric antigen receptor T-cell (CAR-T) therapies.
With continued developments in NHL management, bispecific antibodies are a promising strategy for use in the relapsed/refractory setting with promising data showing potential for improving outcomes in patient care.
https://andro.io/app/nhlar
Power 100
Android app profile
Updates in NHL Management for Android – Latest Version & Features
★★★★★
(0 ratings)
Rate this app
How do you feel about Updates in NHL Management?
Thanks for your feedback!
> 2.2k
Monthly Downloads
~$900
Estimated Cost
Screenshots
